Contract Award

RNS Number : 2422M

Physiomics PLC

26 April 2018

 

26^th April 2018

Physiomics plc

("Physiomics") or ("the Company")

Contract award

Physiomics signs agreement with new biotech client

Physiomics plc (AIM: PYC), a provider of technology-based solutions to predict the effects of cancer treatment regimens for the biopharma industry, is delighted to announce that it has been awarded a contract by a new UK based biotech client.  The value of the contract is £48k and it is expected to complete in this calendar year.

The project will focus on the translation of pre-clinical to clinical results in support of a first in man study of a novel cancer drug.  This is an area of increasing focus for Physiomics and one where it believes its technology and experience can really add value whether working for small biotechnology or global pharmaceutical companies.

Dr Jim Millen, CEO said: "We are pleased that we are keeping up the momentum of new business contracts following on from the previously announced signing of deals with three big pharmaceutical companies in the last six months."

Enquiries:

Physiomics plc                                                   

Dr Jim Millen, CEO

[phone]

WH Ireland Limited (nomad)

Katy Mitchell

[phone]

Hybridan LLP (broker)

Claire Louise Noyce

[phone]

Notes to Editor

About Physiomics

Physiomics plc (AIM: PYC) is a solutions provider to the R&D based pharmaceutical and biotechnology industry with a focus on oncology. The Company's Virtual Tumour technology uses computer modelling to predict the effects of cancer drugs and treatments to improve the success rate of drug discovery and development projects while reducing time and cost. The predictive capability of Virtual Tumour has been confirmed by 55 projects, involving over 25 targets and 60 drugs, and has worked with clients such as Merck KGaA, Merck & Co, Bayer and Lilly.

Based in Oxford UK, the Company works with clients worldwide to support their pre-clinical and clinical oncology development programs. Its team of scientists and computer modelling experts provide bespoke solutions encompassing data, analytics and insight.

Physiomics senior management has academic and commercial expertise, including over 90 years collectively of working in oncology and/or computational biology and over 100 publications in peer reviewed journals.

For more information please visit:

www.physiomics-plc.com

www.twitter.com/Physiomics

www.linkedin.com/company/physiomics-plc/

 

END

 

 

CNTPGUCUCUPRGUQ